Posted by Michael Wonder on 15 Oct 2022
CHMP recommends conditional marketing authorisation for spesolimab as first in class treatment option for generalised pustular psoriasis flares
14 October 2022 - CHMP positive opinion is based on evidence from the EFFISAYIL® 1 trial, the largest clinical trial in patients with generalized pustular psoriasis (GPP) flares.
The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the granting of a conditional market authorization* for Boehringer Ingelheim’s spesolimab as first in class treatment option for generalized pustular psoriasis (GPP) flares in adults.
